

# ITGAV (heavy chain, Cleaved-Lys889) Antibody

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP50036

## Product Information

---

<b>Application</b>	WB
<b>Primary Accession</b>	<a href="#">P06756</a>
<b>Reactivity</b>	Human
<b>Host</b>	Rabbit
<b>Clonality</b>	polyclonal
<b>Calculated MW</b>	116038

## Additional Information

---

<b>Gene ID</b>	3685
<b>Other Names</b>	Integrin alpha-V, Vitronectin receptor subunit alpha, CD51, Integrin alpha-V heavy chain, Integrin alpha-V light chain, ITGAV, MSK8, VNRA
<b>Dilution</b>	WB~~ 1:1000
<b>Format</b>	Rabbit IgG in phosphate buffered saline (without Mg <sup>2+</sup> and Ca <sup>2+</sup> ), pH 7.4, 150mM NaCl, 0.09% (W/V) sodium azide and 50% glycerol.
<b>Storage Conditions</b>	-20°C

## Protein Information

---

<b>Name</b>	ITGAV ( <a href="#">HGNC:6150</a> )
<b>Function</b>	The alpha-V (ITGAV) integrins are receptors for vitronectin, cytотactин, fibronectin, fibrinogen, laminin, matrix metalloproteinase- 2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1- dependent fractalkine signaling (PubMed: <a href="#">23125415</a> ). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed: <a href="#">20682778</a> ). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed: <a href="#">18441324</a> ). ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling (PubMed: <a href="#">28302677</a> ). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed: <a href="#">19578119</a> ). ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed: <a href="#">28873464</a> ). ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling (PubMed: <a href="#">29030430</a> ). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed: <a href="#">18635536</a> , PubMed: <a href="#">25398877</a> ). ITGAV:ITGB3 and ITGAV:ITGB6 act as

receptors for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1 (PubMed:[12807887](#), PubMed:[17158881](#)). Integrin alpha-V/beta-6 or alpha- V/beta-8 (ITGAV:ITGB6 or ITGAV:ITGB8) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF- beta-1 activation (PubMed:[15184403](#), PubMed:[22278742](#), PubMed:[28117447](#)). ITGAV:ITGB3 acts as a receptor for CD40LG (PubMed:[31331973](#)). ITGAV:ITGB3 acts as a receptor for IBSP and promotes cell adhesion and migration to IBSP (PubMed:[10640428](#)).

#### Cellular Location

Cell membrane; Single-pass type I membrane protein. Cell junction, focal adhesion


## Background

The alpha-V integrins are receptors for vitronectin, cytотactин, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

## References

- Suzuki S.,et al.J. Biol. Chem. 262:14080-14085(1987).  
Sims M.A.,et al.Cytogenet. Cell Genet. 89:268-271(2000).  
Ota T.,et al.Nat. Genet. 36:40-45(2004).  
Totoki Y.,et al.Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.  
Hillier L.W.,et al.Nature 434:724-731(2005).

## Images



Western blot analysis of lysates from HUVEC,A549 cell line (from left to right),using ITGAV (heavy chain, Cleaved-Lys889) Antibody(L0297). L0297 was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:5000 dilution was used as the secondary antibody.Lysates at 35ug per lane.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.